A Multiple Dose Escalation Study of ASKP1240 in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to explore the safety and tolerability of multiple doses of
ASKP1240 compared to placebo and determine Pharmacokinetics and Pharmacodynamics in subjects
with moderate to severe psoriasis.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborators:
Kyowa Hakko Kirin Company, Limited Kyowa Kirin Co., Ltd.